Fendrix与Engerix-B在炎症性肠病患者乙肝疫苗初次接种中的随机对照试验
该随机对照试验纳入173例炎症性肠病患者,1:1分配接受Engerix-B双倍剂量或Fendrix单剂量,于0、1、2、6月接种。第4剂后Fendrix组应答率75% vs Engerix-B组68%(P=0.3),疫苗类型与应答无关;4剂方案优于3剂方案,高龄及使用免疫调节剂或抗TNF药物降低应答。
要点
- Fendrix单剂与Engerix-B双倍剂量在IBD患者中应答率无显著差异。
- 4剂乙肝疫苗方案比3剂方案更有效。
- 高龄及使用激素、免疫调节剂或抗TNF药物降低疫苗应答。
核心结论
- 未能证明Fendrix单剂量在IBD患者中应答率高于Engerix-B双倍剂量。
研究设计与样本
- 随机对照试验,173例IBD患者按1:1随机接受Engerix-B双倍剂量或Fendrix单剂量,于0、1、2、6月接种。
主要发现
- 总体45%患者在3剂后应答(抗-HBs ≥100 IU/L),71%在第四剂后应答。
- 第四剂后应答率Fendrix组75% vs Engerix-B组68%(P=0.3)。
- 高龄及使用激素、免疫调节剂或抗TNF药物与较低应答概率相关,疫苗类型与应答无关。
- 抗-HBs滴度转阴率在6个月后为13%,12个月后为20%。
- 接种后抗-HBs ≥100 IU/L是随访期间维持抗-HBs滴度的唯一相关因素。
临床怎么用
- IBD患者乙肝疫苗接种推荐采用4剂方案而非3剂方案。
- 对高龄或使用免疫调节剂、抗TNF药物的IBD患者应预期较低应答率。
- 接种后抗-HBs ≥100 IU/L者仍需监测滴度,因相当比例随时间转阴。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: To compare Engerix-B and Fendrix hepatitis B virus for primo vaccination in inflammatory bowel disease (IBD). METHODS: Patients with IBD were randomized 1:1 to receive Engerix-B double dose or Fendrix single dose at months 0, 1, 2, and 6. Anti-HBs titers were measured 2 months after the third and fourth doses. Response to vaccination was defined as anti-HBs ≥100 UI/L. Anti-HBs titers were measured 2 months after the third and fourth doses and again at 6 and 12 months after the fourth dose. RESULTS: A total of 173 patients were randomized (54% received Engerix-B and 46% Fendrix). Overall, 45% of patients responded (anti-HBs ≥100 IU/L) after 3 doses and 71% after the fourth dose. The response rate after the fourth dose was 75% with Fendrix vs 68% with Engerix-B (P = 0.3). Older age and treatment with steroids, immunomodulators, or anti-tumor necrosis factor were associated with a lower probability of response. However, the type of vaccine was not associated with the response. Anti-HBs titer negativization occurred in 13% of patients after 6 months and 20% after 12 months. Anti-HBs ≥100 IU/L after vaccination was the only factor associated with maintaining anti-HBs titers during follow-up. DISCUSSION: We could not demonstrate a higher response rate of Fendrix (single dose) over Engerix-B (double dose). A 4-dose schedule is more effective than a 3-dose regimen. Older age and treatment with immunomodulators or anti-tumor necrosis factors impaired the success. A high proportion of IBD patients with protective anti-HBs titers after vaccination loose them over time. The risk of losing protective anti-HBs titers is increased in patients achieving anti-HBs <100 IU/L after the vaccination.
引用
- Chaparro M, Gordillo J, Domènech E, et al. Fendrix vs Engerix-B for Primo-Vaccination Against Hepatitis B Infection in Patients With Inflammatory Bowel Disease: A Randomized Clinical Trial. Am J Gastroenterol. 2020. PMID: 33156099. doi:10.14309/ajg.0000000000000926
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。